AvantGuard News

We're pleased to announce that AvantGuard Inc. has been awarded a $350,000 Phase I grant from the National Institutes of Health to develop an antimicrobial treatment for diabetic foot ulcers—one of the most challenging and costly complications of diabetes care.

We're pleased to announce that AvantGuard Inc. has been awarded a $300,000 Phase I grant from the National Institutes of Health to develop a novel treatment for dermatophytosis—the fungal infection responsible for conditions like ringworm, athlete's foot, and jock itch. This funding validates AvantGuard’s innovative approach to a widespread problem that affects millions and represents a global market exceeding $10 billion annually.

We're excited to announce that AvantGuard Inc. has been awarded a $2 million Phase IIB grant from the National Institutes of Health to advance the development of polyvantoin chlorine, our innovative polymer-based disinfectant designed to address antimicrobial-resistant biofilms in healthcare settings. This funding represents a major milestone in our mission to tackle antimicrobial resistance and validates our innovative approach to one of healthcare's most pressing challenges

We tested AvantGuard’s antiseptic compound, polyvantoin chlorine, against some of the most feared pathogens in modern medicine: pan-resistant Candida auris (now Candidozyma auris ) , multidrug-resistant ESKAPE bacteria, and a comprehensive panel of dangerous fungi. The results revealed something remarkable. You might think that an antibiotic-resistant pathogen is somehow tougher and harder for any compound to kill. However, whether the pathogen was resistant or susceptible t